Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2014) 35 P211 | DOI: 10.1530/endoabs.35.P211

ECE2014 Poster Presentations Clinical case reports Pituitary/Adrenal (50 abstracts)

Can bexarotene be a candidate drug for the medical therapy of Cushing's syndrome?

Hulusi Atmaca 1 , Gülsen Isikli 2 , Nilgün Senturk 3 & Piltan Büyükkaya 4

1Department of Endocrinology and Metabolism, Ondokuz Mayis University Medical School, Samsun, Turkey; 2Department of Internal Medicine, Ondokuz Mayis University Medical School, Samsun, Turkey; 3Department of Dermatology, Ondokuz Mayis University Medical School, Samsun, Turkey; 4Department of Hematology, Ondokuz Mayis University Medical School, Samsun, Turkey.

We report a patient with mycosis fungoides treated with bexarotene (Targretin), a synthetic retinoid analog with specific affinity for retinoid X receptor. This patient developed hypopituitarism characterized by hypogonadism, hypothyroidism, and hypoadrenalism. Although central hypothyroidism is a common side effect of bexarotene, central hypogonadism, and hypoadrenalism has been reported in one case. Clinicians should have high index of suspicion for hypopituitarism in patients under bexarotene therapy. On the other hand, this side effect may be promising for the treatment of TSH-secreting pituitary tumours and Cushing’s syndrome. In this regard we suggest that bexarotene should be evaluated as a potential therapy for Cushing’s syndrome in which the available medical drugs have limited efficacy and potential side effects.

Article tools

My recent searches

No recent searches.